---
title: "Genenta Science Warned by Nasdaq Over Minimum Bid Price Compliance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282741414.md"
description: "Genenta Science S.p.A. has been notified by Nasdaq that its American Depositary Shares (GNTA) are below the minimum bid price requirement of $1 per share, following a trading period from February 26 to April 9, 2026. The company has 180 days to regain compliance, with the possibility of an extension. Genenta is exploring options to stabilize its share price and maintain its Nasdaq listing, which is crucial for future capital-raising. The latest analyst rating for GNTA is a Buy with a $7.00 price target."
datetime: "2026-04-14T20:28:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282741414.md)
  - [en](https://longbridge.com/en/news/282741414.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282741414.md)
---

# Genenta Science Warned by Nasdaq Over Minimum Bid Price Compliance

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Genenta Science SpA Sponsored ADR ( (GNTA) ) just unveiled an announcement.

On April 10, 2026, Genenta Science S.p.A. received notice from Nasdaq that its American Depositary Shares no longer met the exchange’s minimum bid price requirement of $1 per share, after the stock traded below that threshold between February 26 and April 9, 2026. The deficiency does not immediately affect the listing, but the company now has 180 days, until October 7, 2026, to regain compliance, with the potential for an additional 180 days if it meets other listing criteria and pursues measures such as a reverse stock split.

Genenta said it is evaluating options to restore compliance and intends to meet Nasdaq’s continued listing standards, though it cautioned there is no assurance it will succeed or remain compliant with other requirements. The disclosure, filed on April 14, 2026, underscores the pressure on the company to stabilize its share price and preserve its Nasdaq Capital Market listing, a key platform for investor access and future capital-raising efforts.

The most recent analyst rating on (GNTA) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Genenta Science SpA Sponsored ADR stock, see the GNTA Stock Forecast page.

**More about Genenta Science SpA Sponsored ADR**

Genenta Science S.p.A. is a biotechnology company listed on Nasdaq via American Depositary Shares. The Milan-based firm focuses on developing genetic and cell therapies, positioning itself within the life sciences sector and relying on public equity markets for funding and visibility in the U.S. capital markets.

**Average Trading Volume:** 1,087,323

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $15.68M

### Related Stocks

- [GNTA.US](https://longbridge.com/en/quote/GNTA.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Pharma giants commit $500B to US amid tariff threat](https://longbridge.com/en/news/289866895.md)